{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Welcome to the Arena from ICR – Conversations with Today's Innovators & Business Leaders","title":"Jim Clemmer, CEO, AngioDynamics – To Your Health: The economics of med tech innovation","html":"","width":"100%","height":180,"duration":1644,"description":"Innovating in the field of Med Tech presents a host of unique challenges. Formulating new treatments is a long and capital-intensive process. The regulatory regime for medical devices is extremely stringent. And even if you get approval, you still need to convince doctors that your treatment is safe and effective. But success in Med Tech R & D doesn't just mean profits for the company and it's shareholders, it means new treatments that can dramatically improve or even save the lives of patients. \n\nJim Clemmer became the CEO of AngioDynamics in April of 2016, the company trades on the NASDAQ under the symbol ANGO. Prior to joining the company, Jim served as President of the multi-billion dollar medical supply segment at Covidien PLC where he directed the strategic and day-to-day operations for global business divisions that collectively manufactured 23 different product categories. In addition, he managed global manufacturing, research and development, operations, business development, and all other functions associated with the medical supplies business.\n \nJim joins us to discuss AngioDynamics' innovative products that are helping treat a range of conditions from pulmonary embolism to prostate cancer. He also explains how their continued commitment to innovation has set AngioDynamics up for future success. \n \nHighlights:\nThe AngioDynamics Mission (4:03)\nManaging the AngioDynamics Portfolio (5:04)\nWhat sets AngioDynamics apart in the field (6:20)\nMeeting real-world clinical needs (7:24)\nAngioDynamics products (8:53)\nAngioDynamics approach to R&D (12:45)\nThe impact on patients (15:36)\nNavigating regulation in different markets (20:06)\nThe role of AI (21:35)\nAngioDynamics' balance sheet (23:01) \nLinks:\nAngioDynamics LinkedIn\nAngioDynamics Website\nICR LinkedIn\nICR Twitter\nICR Website\n \nFeedback:\nIf you have questions about the show, or have a topic in mind you'd like discussed in future episodes, email our producer, marion@lowerstreet.co.","thumbnail_url":"https://img.transistorcdn.com/VPbFZOgoHk78hrWlplrfMSrQROUNxI8jcZ2Gv-hyKm4/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9mYmFh/NWFlNGJjY2Y0NGFk/YmM2NWJiMTI4NmVh/OWQ4Yi5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}